6 analysts have expressed a variety of opinions on SpringWorks Therapeutics (NASDAQ:SWTX) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table ...
Investors with a lot of money to spend have taken a bearish stance on SpringWorks Therapeutics (NASDAQ:SWTX). And retail traders should know. We noticed this today when the trades showed up on ...
A SpringWorks Therapeutics drug has won FDA approval for treating a rare connective tissue tumor, making it the first approved therapy for this type of tumor. It’s also the first product approval for ...
Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...
Despite the recent approval of SpringWorks Therapeutics’ Ogsiveo, GSK is calling it quits on prior plans to wed the Pfizer spinout’s drug with its withdrawn cancer med Blenrep. SpringWorks on Thursday ...
Add Yahoo as a preferred source to see more of our stories on Google. Apr. 21—LISBON — As Springworks Farm celebrates 10 years in business this year, head grower Brady Sinclair is notching his first ...
STAMFORD, Conn., Dec. 04, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that ...
GSK helps SpringWorks to double payday from boosted combo deal as it also reels $225M in new funding
It’s a good day to be the CFO of SpringWorks Therapeutics. The precision medicine biotech has not only secured $225 million in funding, but also banked a further $75 million equity investment as part ...
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease drugmaker has attracted the attention of a biopharma bigwig from overseas.
SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to loss of $1.18 per share a year ago. These ...
When it comes to the calendar of months dedicated to raising awareness of illnesses or medical conditions, a few may come to mind. October is for raising awareness of breast cancer, May is for mental ...
Investment merits have increased materially since my last article with more support for its approved therapy and pipeline advancements. Ample liquidity supports its operations and pipeline development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results